What is Immutep?
Established in 2001 and headquartered in Sydney, New South Wales, Immutep operates at the intersection of immunology and therapeutic innovation. The company focuses on the development of novel LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune diseases. By targeting the LAG-3 immune control mechanism, Immutep aims to enhance the body's natural immune response against malignant cells. Their market position is defined by a robust intellectual property portfolio and a series of ongoing clinical trials that evaluate the efficacy of their lead candidates in combination with existing standard-of-care therapies. As a specialized biotech entity, Immutep bridges the gap between fundamental immunological research and practical clinical application, providing a critical contribution to the global oncology ecosystem.
How much funding has Immutep raised?
Immutep has raised a total of $140M across 3 funding rounds:
Share Placement
$7M
Other Financing Round
$80M
Other Financing Round
$53M
Share Placement (2019): $7M, investors not publicly disclosed
Other Financing Round (2023): $80M, investors not publicly disclosed
Other Financing Round (2024): $53M, investors not publicly disclosed
Key Investors in Immutep
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Immutep?
With the successful completion of this major strategic investment, Immutep is expected to prioritize the advancement of its late-stage clinical programs. The capital will likely be deployed to support the operational requirements of multi-center trials and to bolster the regulatory submission processes for its lead therapeutic candidates. Furthermore, the firm is anticipated to explore strategic partnerships that could enhance the commercialization potential of its proprietary technology. As the company moves into this next phase of growth, the focus remains on achieving key clinical milestones that demonstrate long-term value for stakeholders and, more importantly, improved outcomes for patients undergoing immunotherapy treatment. The sustained financial backing reflects a long-term commitment to the company's vision of transforming cancer care through targeted immune modulation.
See full Immutep company page
